PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis

被引：211

作者：

Bykov, VJN

Zache, N

Stridh, H

Westman, J

Bergman, J

Selivanova, G

Wiman, KG ^{[1
]}

机构：

[1] CCK, Dept Oncol Pathol, Stockholm, Sweden

[2] Aprea AB, Stockholm, Sweden

[3] Novum, Dept Biosci, Stockholm, Sweden

[4] Karolinska Inst, Ctr Microbiol & Tumor Biol, Stockholm, Sweden

来源：

ONCOGENE | 2005年 / 24卷 / 21期

关键词：

p53; mutation; cancer therapy; chemotherapeutic drugs; PRIMA-1; synergy;

D O I：

10.1038/sj.onc.1208419

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Mutant p53-carrying tumors are often more resistant to chemotherapeutical drugs. We demonstrate here that the mutant p53-reactivating compound PRIMA-1(MET) acts synergistically with several chemotherapeutic drugs to inhibit tumor cell growth. Combined treatment with cisplatin and PRIMA-1(MET) resulted in a synergistic induction of tumor cell apoptosis and inhibition of human tumor xenograft growth in vivo in SCID mice. The induction of mutant p53 levels by chemotherapeutic drugs is likely to increase the sensitivity of tumor cells to PRIMA-1(MET). Thus, the combination of PRIMA-1(MET) with currently used chemotherapeutic drugs may represent a novel and more efficient therapeutic strategy for treatment of mutant p53-carrying tumors.

引用

页码：3484 / 3491

页数：8

共 24 条

[1] COMPLETE SEQUENCING OF THE P53 GENE PROVIDES PROGNOSTIC INFORMATION IN BREAST-CANCER PATIENTS, PARTICULARLY IN RELATION TO ADJUVANT SYSTEMIC THERAPY AND RADIOTHERAPY [J].